Reproductive health hazards in the pharmaceutical industry.
The continual development of new compounds and the ongoing search for more potent drugs and new technologies in the pharmaceutical industry present a challenging environment for the recognition and evaluation of reproductive health hazards. This chapter discusses toxicology and offers an overview of the organization and implementation of a reproductive health program.
Clement
J D
JD
Occupational Health Services, Abbott Laboratories, Abbott Park, Illinois, USA.
D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control; D004345:Drug Industry; D004784:Environmental Monitoring / Q000379:methods; D005260:Female; D015386:Hazardous Substances / Q000009:adverse effects*; D006293:Health Promotion / Q000458:organization & administration; D006801:Humans; D008297:Male; D016273:Occupational Exposure / Q000009:adverse effects*; D016272:Occupational Health; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000209:etiology* / Q000517:prevention & control; D011848:Radioactive Pollutants / Q000009:adverse effects*; D012098:Reproduction / Q000187:drug effects* / Q000528:radiation effects*; D018570:Risk Assessment; D014116:Toxicology / Q000379:methods; D014481:United States; D014777:Virus Diseases / Q000209:etiology / Q000517:prevention & control
D015386:Hazardous Substances; D011848:Radioactive Pollutants